VRG Therapeutics Announces Monthly Dosing for Its Lead Program Targeting Kv1.3 for the Treatment of Atopic Dermatitis and Other Chronic Inflammatory Diseases
Infrastructure
September 4, 2024
By VRG Therapeutics
VRG Therapeutics is expanding into the Netherlands!
AI
Team
July 29, 2024
By VRG Therapeutics
VRG Therapeutics has been selected among the "Early Stage Startups to Watch" in the drug discovery space by Sifted!
Kv1.3
July 11, 2024
By VRG Therapeutics
New VRG Tx patent application filed!
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
CREATe-1
May 24, 2024
By VRG Therapeutics
Publication - Chemogenetic Inhibition of the Lateral Hypothalamus Effectively Reduces Food Intake in Rats in a Translational Proof-of-Concept Study
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.